BriaCell Therapeutics annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
BriaCell Therapeutics Stock-Based Compensation Growth & History (BCTX)
BriaCell Therapeutics's stock-based compensation was $776,879 for fiscal 2025.
View full BriaCell Therapeutics company overviewBriaCell Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-07-31 | $776,879 | −$1.0M | −56.94% |
| 2024 | 2024-07-31 | $1.8M | −$389,712 | −17.76% |
| 2023 | 2023-07-31 | $2.2M | −$880,794 | −28.65% |
| 2022 | 2022-07-31 | $3.1M | $1.1M | +56.21% |
| 2021 | 2021-07-31 | $2.0M | $2.0M | +116639.38% |
| 2020 | 2020-07-31 | $1,686 | −$47,631 | −96.58% |
| 2019 | 2019-07-31 | $49,317 | — | — |
BriaCell Therapeutics quarterly stock-based compensation
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-04-30 | $432,207 | $207,392 | +92.25% |
| Q2 2026 | 2026-01-31 | $285,856 | $763 | +0.27% |
| Q1 2026 | 2025-10-31 | $294,686 | $27,715 | +10.38% |
| Q4 2025 | 2025-07-31 | $0 | −$377,892 | — |
| Q3 2025 | 2025-04-30 | $224,815 | −$167,400 | −42.68% |
| Q2 2025 | 2025-01-31 | $285,093 | −$215,062 | −43.00% |
| Q1 2025 | 2024-10-31 | $266,971 | −$266,845 | −49.99% |
| Q4 2024 | 2024-07-31 | $377,892 | −$155,924 | −29.21% |
| Q3 2024 | 2024-04-30 | $392,215 | $111,026 | +39.48% |
| Q2 2024 | 2024-01-31 | $500,155 | $233,311 | +87.43% |
| Q1 2024 | 2023-10-31 | $533,816 | −$578,125 | −51.99% |
| Q4 2023 | 2023-07-31 | $533,816 | −$344,131 | −39.20% |
| Q3 2023 | 2023-04-30 | $281,189 | −$582,438 | −67.44% |
| Q2 2023 | 2023-01-31 | $266,844 | −$548,032 | −67.25% |
| Q1 2023 | 2022-10-31 | $1.1M | $593,807 | +114.60% |
| Q4 2022 | 2022-07-31 | $877,947 | — | — |
| Q3 2022 | 2022-04-30 | $863,627 | −$1.1M | −56.98% |
| Q2 2022 | 2022-01-31 | $814,876 | — | — |
| Q1 2022 | 2021-10-31 | $518,134 | — | — |
| Q3 2021 | 2021-04-30 | $2.0M | — | — |
BriaCell Therapeutics stock-based compensation trends
Over the last five fiscal years, BriaCell Therapeutics's stock-based compensation increased from $1,686 to $776,879, a change of $775,193. The latest reported quarter, Q3 2026, shows $432,207.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BriaCell Therapeutics source filings ↗